Ankylosing spondylitis (AS) is a chronic inflammatory disease primarily affecting the spine and sacroiliac joints, leading to pain and stiffness. As a type of axial spondyloarthritis, it can significantly impact quality of life by reducing mobility and causing persistent discomfort. Historically, treatment options have been limited, focusing mainly on symptom management through nonsteroidal anti-inflammatory drugs (NSAIDs) and biologics like tumor necrosis factor (TNF) inhibitors. However, recent advancements in understanding the pathophysiology of AS have opened new avenues for therapeutic intervention.

Understanding the Disease Mechanism

The pathogenesis of ankylosing spondylitis involves a complex interplay of genetic, environmental, and immunological factors. The human leukocyte antigen B27 (HLA-B27) is strongly associated with AS, although its exact role remains elusive. It is hypothesized that HLA-B27 may misfold, leading to an inflammatory response. Additionally, the involvement of cytokines such as interleukin-17 (IL-17) and interleukin-23 (IL-23) has been identified as crucial in the inflammatory pathways that drive the disease.

Understanding these mechanisms has b...